News & Investors

Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Cara Therapeutics Announces Dosing of Patients in Phase 2 Trial of Oral KORSUVA™ (CR845/difelikefalin) for Pruritus in Stage III-V Chronic Kidney Disease (CKD) Patients
Completed Phase 1 trial establishes Oral KORSUVA tablet strengths for treatment of CKD-associated pruritus STAMFORD, Conn., July 11, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed
View HTML
Toggle Summary Cara Therapeutics Reports Positive Top-Line Data from Adaptive Phase 2/3 Trial of I.V. CR845 in Patients Undergoing Abdominal Surgery
-I.V. CR845 achieved statistical significance for the study’s primary endpoint of pain relief over the 0 to 24-hour (AUC 0-24) period post-surgery for combined surgeries at the 1.0 mcg/kg dose (p=0.032)- -I.V. CR845 treatment resulted in statistically significant reductions in the secondary
View HTML
Toggle Summary Cara Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
STAMFORD, Conn. , May 29, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Enter into Ex-U.S. Licensing Agreement to Commercialize KORSUVA™ Injection in Dialysis Patients with Pruritus
Cara receives upfront payment of $50 million in cash and an equity investment of $20 million Cara eligible for up to $470 million in regulatory and commercial milestones VFMCRP to commercialize KORSUVA injection worldwide except in the U.S., Japan and South Korea Cara to commercialize KORSUVA
View HTML
Toggle Summary Cara Therapeutics to Present at the International Investigative Dermatology 2018 Meeting
STAMFORD, Conn. , May 14, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Reports First Quarter 2018 Financial Results
Conference call today at 4:30 p.m. ET STAMFORD, Conn. , May 09, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral
View HTML
Toggle Summary Cara Therapeutics to Announce First Quarter 2018 Financial Results on May 9, 2018
STAMFORD, Conn. , May 02, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Announces Participation in 2018 Spring Clinical Meetings of the National Kidney Foundation
STAMFORD, Conn. , April 10, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML
Toggle Summary Cara Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
Conference call today at 4:30 p.m. ET STAMFORD, Conn. , March 15, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid
View HTML
Toggle Summary Cara Therapeutics to Announce Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
STAMFORD, Conn. , March 08, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced
View HTML